Name | compound 21 [PMID: 22802221] |
---|---|
Synonyms |
Butyl ({3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-isobutyl-2-thienyl}sulfonyl)carbamate
butyl ({3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl}sulfonyl)carbamate compound 21 [PMID: 22802221] Carbamic acid, N-[[3-[4-(1H-imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)-2-thienyl]sulfonyl]-, butyl ester N-butyloxycarbonyl-3-(4-imidazol-1-ylmethylphenyl)-5-isobutylthiophene-2-sulfonamide |
Description | AT2 receptor agonist C21 is a druglike selective angiotensin II AT2 receptor agonist with Ki values of 0.4 nM and >10 µM for the AT2 receptor and AT1 receptor, respectively[1]. |
---|---|
Related Catalog | |
Target |
Ki: 0.4 nM (AT2) and >10 µM (AT1)[1] |
In Vivo | AT2 receptor agonist C21, with a bioavailability of 20-30% after oral administration and a half-life estimated to 4 h in rat, induces outgrowth of neurite cells, stimulates p42/p44mapk, enhances in vivo duodenal alkaline secretion in Sprague-Dawley rats, and lowers the mean arterial blood pressure in anesthetized, spontaneously hypertensive rats[1]. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Molecular Formula | C23H29N3O4S2 |
Molecular Weight | 475.624 |
Exact Mass | 475.159943 |
LogP | 4.93 |
Index of Refraction | 1.615 |